Skye Bioscience Inc (SKYE): NMUS is steering their development effor...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Skye Bioscience Inc (SKYE)

Reply Private New

Keep Last Read

Replies (4) Next 10 Prev Next

Send PM Follow Ignore

Followers	99
Posts	2765
Boards Moderated	2
Alias Born	02/10/2004

Re: TheMonolith post# 4898

Monday, 04/30/2018 7:34:50 AM

Monday, April 30, 2018 7:34:50 AM

NMUS is steering their development efforts right into that hot spot of abuse deterrent and opiod alternatives to pain managment that Dr. Gupta is talking about too, take note of slide #34 of their March 2018 slide deck (available on bottom of their homepage), their NB2111 program is now targeting "Pain Syndromes" more broadly than their previous "Chemotherapy Induced Neuropathy" target discussed in previous presentations and the development timeline has them ready for a clinical POC study early next year now!

Previously, they had their NB1222 for Chemotherapy Induced Nausea and Vomiting (CINV) was higher priority, but now it is "Prioritization Pending Further Market Analysis"....which I suspect means they are shopping for a partner to fund that now, to allow them to use their funds to pursue the big fish of "Pain Syndromes".

NMUS sure looks cheap relative to competitors when you consider the size of the markets they are going after.

"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854

Keep Last Read

Replies (4) Next 10 Prev Next

Recent SKYE News

Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:33:12 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:32:26 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:30:29 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:29:19 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:28:15 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:25:57 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 12:25:01 AM
Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 09:25:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 08:59:55 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/23/2024 09:25:23 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 10:56:11 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/13/2024 09:18:32 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:12:34 PM
Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:25:07 PM
Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 09:29:35 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:18:47 PM
Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND™ Phase 2 Trial of Nimacimab for Obesity • GlobeNewswire Inc. • 07/24/2024 11:30:00 AM
Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 01:27:39 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/20/2024 04:15:09 AM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/17/2024 08:27:44 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:19:14 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 08:17:16 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:02:13 PM

More SKYE News

InvestorsHub NewsWire

VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM

Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM

North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM

Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM

CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM

Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow